Bristol Myers Squibb, a biopharmaceutical company, completed the acquisition of a minority stake in Kura Oncology, a clinical-stage biopharmaceutical company, for $25m. “Bristol Myers Squibb has deep expertise and history in advancing transformational cancer treatments. This equity investment strengthens the relationship between our organizations and enables Bristol Myers Squibb to provide valuable strategic input into our global development strategy. We are honored and excited to have their support and look forward to their input as we work to deliver innovative science with the potential to benefit patients," Troy Wilson, Kura Oncology CEO.